LBLouis J. Bont

Louis J. Bont

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Louis J. Bont has a total of 909 co-authors. Here are the top co-authors by number of shared publications:

  • Harish Nair

    Centre for Global Health, Usher Institute, The University of Edinburgh, Edinburgh, UK

    14 shared publications
  • Maroeska M. Rovers

    Department of Medical Imaging, Radboudumc, Nijmegen, The Netherlands

    13 shared publications
  • Federico Martinón-Torres

    Genetics, Vaccines and Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) , Santiago de Compostela, Galicia

    9 shared publications
  • Joanne G Wildenbeest

    Department of Paediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Centre Utrecht , Utrecht

    9 shared publications
  • Maarten O. Blanken

    Division of Pediatric Immunology and Infectious Diseases, University Medical Center Utrecht, P.O. Box 85090, 3508 AB, Utrecht, the Netherlands

    9 shared publications
  • Natalie I Mazur

    Department of Paediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands

    8 shared publications

Latest Publications

  • Open Access

    RSM01, an extended half-life RSV monoclonal antibody with a high barrier to in vitro resistance

    by Jonne Terstappen, Emanuele C. Gustani Buss, Cassandra A. L. Simonich, Jason S. McLellan, Vicky-Lynne Baillie, Jesse D. Bloom, Louis J. Bont, Mauricio T. Caballero, Klasina Chappin, Janissa J. A. van Duijn, et al.

    Respiratory syncytial virus (RSV) causes substantial infant morbidity and mortality, particularly in low- and middle-income countries (LMICs). RSM01 is a long-acting RSV monoclonal antibody (mAb) in development for LMICs. In vitro generation of RSM01 resistant mutants has previously been unsuccessful. We systematically assessed the in vitro resistance barrier of RSM01 and the susceptibility of a panel of global contemporary strains to RSM01. Monoclonal antibody resistant mutants (MARMs) were generated by serially passaging triple plaque-purified RSV-A2 and RSV-B1 using HEp-2 cells under pressure from RSM01, nirsevimab, or palivizumab, followed by phenotypic and genotypic characterisation. Moderate resistance was defined as > 3-fold and high resistance as > 30-fold increase in IC 50 compared with parental virus. The susceptibility of contemporary global clinical strains to RSM01 was tested in a neutralisation assay. RSV-A and B strains developed high resistance to palivizumab and nirsevimab, while RSM01 pressure induced moderate resistance. No MARMs demonstrated a fitness advantage. RSM01 neutralised global contemporary strains. In conclusion, in vitro RSM01 resistance was infrequent and moderate and RSM01 had broad activity against circulating strains. The confirmation of the high barrier to resistance of RSM01 is encouraging and provides an alternative should resistance emerge with widespread use of current licensed anti-RSV mAbs.

  • Open Access

    Placental Histopathology and Transplacental Transfer of RSV-specific Neutralizing Antibodies The Silver Study

    by Emily W. E. M. Phijffer, Joukje Willemsen, Joanne G. Wildenbeest, Larry J. Anderson, Kitty W. M. Bloemenkamp, Floris Groenendaal, Peter G. J. Nikkels, Louis J. Bont

    Background: Maternally acquired passive immunity via transplacental antibody transport is crucial for the protection of infants against infectious diseases in early life. We examined whether placental histological characteristics impact the transplacental transfer of natural respiratory syncytial virus (RSV)-specific neutralizing antibodies. Methods: We performed a prospective, observational, cross-sectional study. Pregnant women were enrolled with a 1:1:1 inclusion ratio of extremely preterm-born infants (24–32 weeks), moderately preterm-born infants (33–36 weeks) and term-born infants (37–42 weeks). Cord–maternal ratios (CMRs) for serum neutralizing RSV-A and -B antibodies were analyzed in relation to 16 placental histologic characteristics. Results: In total, 85 mother–infant pairs were available for analysis. Infant gestational age was significantly correlated with CMRs for RSV-A and -B specific antibodies ( B = 0.10, P < 0.001). Although a few placental characteristics showed a univariate association with CMR, the multivariate model showed that only gestational age was independently related to CMR ( B = 0.11, P < 0.001). Conclusions: Our study confirms that CMRs increase during gestation. However, variations in placental histology may not affect transplacental RSV-A and RSV-B antibody transfer. We hypothesize that the placental compensatory capacity and active transport mechanism may play a key role in transplacental antibody transfer.

  • Open Access

    Low Cord Blood Titers Are Associated With Prolonged Maternal Respiratory Syncytial Virus Antibody Half-Lives in Preterm Infants

    by Joukje E Willemsen, Emily W E M Phijffer, Joanne G Wildenbeest, Larry J Anderson, Binh Ha, Ranjini Sankaranarayanan, Floris Groenendaal, Kitty W M Bloemenkamp, José A M Borghans, Julia Drylewicz, et al.

    Background: Preterm infants are at higher risk of severe respiratory syncytial virus (RSV) infection, partially because of reduced placental transfer of maternal antibodies (Abs). Increased risk of severe infection persists in the first year of life. This study evaluates the postnatal kinetics of RSV-neutralizing Abs in preterm and full-term infants born to unvaccinated mothers. Methods: We enrolled infants with a gestational age (GA) of 24–42 weeks born in hospital from RSV-unvaccinated mothers. Serum was collected at birth (cord blood), 1–2 weeks, and 4–8 weeks. Linear mixed-effects models were used to estimate half-lives of RSV-neutralizing Abs in relation to GA and cord blood titer. Analyses were repeated for total serum immunoglobulin G1 (IgG1) to confirm the robustness of our findings. Results: Of 169 infants, 95 were born preterm (<37 weeks GA, including 53 neonates <32 weeks GA). Premature birth was related to prolonged half-life of RSV-neutralizing Abs (approximately 79 days very preterm to approximately 30 days in term infants). The inverse association between GA and Ab half-life was largely accounted for by an inverse association between cord blood Ab levels and Ab half-life. A doubling in cord blood titers led to a reduction in half-life of approximately 20% for RSV-neutralizing Abs and approximately 32% for IgG1. Conclusions: Postnatal Ab half-life depends on starting levels: higher titers decline faster. If our observation would be replicated for vaccine-induced Abs, the difference in vaccine protection between preterm and term infants may be smaller than anticipated.

  • Open Access

    The economic burden of respiratory syncytial virus and other acute respiratory infections among children <2 years old seeking care at a tertiary facility in Accra, Ghana

    by Farina Leonie Shaaban, Joycelyn Dame, An Nguyen, Neele Rave, Clint Pecenka, Louis J Bont, RSV GOLD III – Health Economics Study Group

    Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections (ALRIs), particularly in infants and young children, causing a considerable health burden. More than three million RSV-ALRI hospital admissions and over 100 000 RSV-attributable deaths are estimated to occur in children <5 years old each year globally. Children in low- and middle-income […]

  • Open Access

    Impact and cost-effectiveness of two interventions to prevent paediatric respiratory syncytial virus disease in Cameroon: a modelling approach

    by Farina Leonie Shaaban, Norbert Fuhngwa, Henshaw Mandi, Andrew Clark, Neele Rave, Clint Pecenka, Louis J Bont, Frédéric Debellut, RSV GOLD III – Health Economics Study Group

    Acute lower respiratory tract infections (ALRIs) associated with respiratory syncytial virus (RSV) cause substantial morbidity and mortality in children under five years of age. An international pneumonia aetiology study found that RSV was the most frequent cause of severe pneumonia (31% of cases) [1]. Most RSV-related health burden (95% of morbidity and 97% of […]

  • Open Access

    Pre-assembly of biomolecular condensate seeds drives RSV replication

    by Dhanushika Ratnayake, Marie Galloux, Sanne Boersma, Marko Noerenberg, Christina Sizun, Carlos Sacristan, Julien Sourimant, Anke J. Lakerveld, Anne T. Gelderloos, Leonie Apperloo, et al.

    During infection, many RNA viruses, including respiratory syncytial virus (RSV), form specialized biomolecular condensates, viral factories (VFs), where viral transcription and replication occur1,2. Paradoxically, high protein concentrations are typically required for condensate nucleation3, yet attaining sufficient protein levels in infection is thought to require VFs for viral transcription and replication. Here, to uncover how viruses solve this paradox to establish VFs, we visualized early infection of RSV in real time with single genomic viral ribonucleoprotein (vRNP) resolution. Our results reveal that VFs are nucleated from infecting vRNPs rather than de novo in the cytoplasm. VF nucleation further requires in-virion pre-assembly of viral protein–protein interaction networks on vRNPs to form ‘pre-replication centres’ (PRCs). PRCs are potent condensate nucleation seeds due to their efficient recruitment and retention of viral proteins. The high affinity of PRCs also results in increased association of the viral polymerase and its co-factors, allowing efficient viral transcription even in the absence of VFs. Together, these activities create a feed-forward loop that drives rapid VF formation. PRC assembly depends on in-virion viral protein levels and is highly heterogeneous among virions, explaining cell-to-cell heterogeneity in infection progression, and identifying heterogeneous virions as an important origin of infection heterogeneity. Together, our results show that in-virion pre-assembly of PRCs kick-starts viral condensate nucleation upon host-cell entry and explains cell-to-cell heterogeneity in RSV infection.


  • Open Access

    Normalization of Seasonality and Age Distribution of Pediatric RSV Infection Following the Pandemic Disruption in the Netherlands

    by Neele Rave, Marit E M de Bruijne, Rebecca K Stellato, Michiel A G E Bannier, Daniel M Weinberger, Yvette N Löwensteyn, Joanne G Wildenbeest, Louis J Bont, Marlies Vermaas—Van Putten

    Background: The COVID-19 pandemic caused a global disruption in respiratory syncytial virus (RSV) epidemiology. However, data on RSV epidemiology in the postpandemic period remain limited. We analyzed shifts in RSV seasonality, age distribution, and disease severity among RSV-positive children in the Netherlands before, during, and after the pandemic. Methods: Between May 2021 and April 2024, children under two years of age, admitted with RSV to 47 Dutch hospitals were included in a prospective surveillance study. We compared demographic and clinical characteristics of RSV-positive patients with data from the pre-COVID period (2018–2020), the COVID period and the post-COVID period (2022–2024). Results: A total of 8457 RSV-positive cases were included, with detailed data collected from 2708 patients (13 hospitals). Following an unusual off-season shift and a period of endemic circulation, RSV seasonality has reverted to its typical prepandemic winter pattern. The median age at admission increased from 2.2 months (interquartile range [IQR]: 1.1–5.6) in the prepandemic period to 4.9 months (IQR 1.8–11.4, P < .05) during the summer outbreak (2021). This subsequently returned to prepandemic median age in the winter of 2023/2024 (2.7 months, IQR 1.3–8.0, not significant). We observed no differences in the prevalence of preterm birth or comorbidities among RSV-positive children before, during or after the COVID pandemic. Conclusions: The COVID-19 pandemic profoundly disrupted RSV epidemiology. This prospective study demonstrates a rapid re-establishment of prepandemic patterns, including a return toward the typical age distribution during early childhood.


  • Open Access

    Estimating the economic burden of respiratory syncytial virus infection among children <2 years old seeking care in North-West Nigeria

    by Farina Leonie Shaaban, Maria Ahuoiza Garba, An Nguyen, Clint Pecenka, Neele Rave, Louis J Bont

    Respiratory syncytial virus (RSV) disease burden is highest in low- and middle-income countries; yet data for costs of RSV-related illness in these settings are scarce. We estimated RSV costs of illness to inform decision-making for RSV preventive strategies in Nigeria. This prospective study assessed the costs of care per episode of (severe) acute respiratory infection during one RSV season (April to November 2023). Children <2 years old, were recruited at tertiary inpatient and outpatient facilities in North-West Nigeria and grouped as non-severe (outpatient), severe (inpatient non-intensive care), and life-threatened (intensive care or fatality) cases. Direct medical, direct non-medical, and indirect cost data were collected using caregiver questionnaires at the index visit or day of admission and follow-up and gathered from hospital records at discharge. We summarised average costs in 2023 USD. We included 792 children (mean age 8.7 months) with non-severe (n = 692), severe (n = 52), and life-threatening (n = 48) respiratory infections. Among these groups we confirmed RSV infection in 130 (19%), 19 (37%), and 14 (29%) children. The average societal costs were USD 13 (95% confidence interval (CI) = 11-14), USD 244 (95% CI = 198-290), and USD 179 (95% CI = 120-239) per episode of non-severe, severe, and life-threatening RSV infection, respectively. Costs associated with RSV did not increase stepwise with the severity categories due to small group sizes and fatalities with low costs included in the life-threatened group. For severe RSV, average household costs were over 200% of the national monthly minimum wage. Most households (89%) resorted to personal savings to cover costs. In young children in Nigeria, RSV presented a significant health and economic burden. This study can inform health economic evaluations of emerging RSV pharmaceutical interventions for Nigeria and may be adjusted for rural/urban contexts and level of care.


  • Open Access

    Cost-effectiveness of introducing a maternal vaccine or long-acting monoclonal antibody to prevent infant respiratory syncytial virus disease in Nepal

    by Neele Rave, Arun K Sharma, Ram H Chapagain, An Nguyen, Clint Pecenka, Farina L Shaaban, Louis J Bont, Andrew Clark, RSV GOLD III – Health Economics Study Group

    Acute lower respiratory infections (ALRIs) caused by respiratory syncytial virus (RSV) are a major cause of death and hospital admissions among young children. In 2019, RSV was estimated to cause 33 million cases and 118 000 deaths in children under five years, with more than 95% of the burden in low- and middle-income countries (LMICs) [1]. […]


  • Top Cited Papers
    Open Access

    The path to equitable respiratory syncytial virus prevention for infants: challenges and opportunities for global implementation

    by Farina L Shaaban, Rosalie W Groenendijk, Ranju Baral, Mauricio T Caballero, James E Crowe, Janet A Englund, Ignacio Esteban, Siddhivinayak Hirve, Mark Jit, Alexis M Kalergis, et al.